Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT00899379 Completed - Migraine Headache Clinical Trials

Treatment of Multiple Attacks of Acute Migraine (0462-025)

Start date: April 1995
Phase: Phase 3
Study type: Interventional

A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.

NCT ID: NCT00898677 Completed - Migraine Headache Clinical Trials

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

Start date: September 1995
Phase: Phase 3
Study type: Interventional

A study to compare rizatriptan 10 mg verse sumatriptan 100 mg in the treatment of migraine attacks and duration of relief provided. This study will also provide additional efficacy data on rizatriptan 5 mg and 10 mg for the treatment of migraine.

NCT ID: NCT00897949 Completed - Migraine Headache Clinical Trials

MK0462 in Treatment of Migraine With Recurrence (MK0462-022)

Start date: March 1995
Phase: Phase 3
Study type: Interventional

A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo. The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.

NCT ID: NCT00897104 Completed - Migraine Headache Clinical Trials

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)

Start date: August 1995
Phase: Phase 3
Study type: Interventional

A study to compare rizatriptan (MK0462) 5 mg by mouth (p.o.) and sumatriptan 50 mg p.o. for the acute treatment of a migraine attack.

NCT ID: NCT00894556 Completed - Acute Migraine Clinical Trials

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Start date: June 10, 2009
Phase: Phase 3
Study type: Interventional

A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.

NCT ID: NCT00893737 Completed - Migraine Clinical Trials

"Completeness of Response" Following Treatment With Treximet™ for Migraine

Start date: June 2009
Phase: Phase 4
Study type: Interventional

Many clinical trials may not fully explore criteria that are important to some migraine patients' definition of "complete response." This study offers the opportunity to evaluate the effectiveness of Treximet™ when non-standard criteria are examined (for example, neck pain, irritability or fatigue). Subjects enrolled at 8 investigative sites will complete 2 visits. Subjects will complete a Completeness of Response Survey at Visit 1 considering their usual migraine medication (a triptan) and a Completeness of Response Survey at Visit 2 considering their study medication (Treximet™).

NCT ID: NCT00892203 Completed - Migraine Clinical Trials

Efficacy and Safety of BGG492 in the Treatment of Migraine

Start date: April 2009
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

NCT ID: NCT00884663 Completed - Chronic Migraine Clinical Trials

Candesartan Versus Propranolol for Migraine Prevention

Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.

NCT ID: NCT00883051 Completed - Migraine Disorders Clinical Trials

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

Start date: July 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.

NCT ID: NCT00875784 Completed - Migraine Disorders Clinical Trials

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

Start date: May 6, 2008
Phase: Phase 1
Study type: Interventional

This study will evaluate the exposure of sumatriptan after administration of TREXIMA (sumatriptan 85mg/naproxen sodium 500mg) followed by a subcutaneous IMITREX injection (4mg or 6mg) 2 hours later compared to administration of a IMITREX 100mg tablet followed by a IMITREX 100mg tablet 2 hours later.